Form 4: MAIA Biotechnology Head of Finance Acquires Stock Options

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Summary

• Jeffrey Himmelreich, the Head of Finance at MAIA Biotechnology, Inc., filed a Form 4 to report changes in beneficial ownership.
• The reported transaction involves the acquisition of 10,000 stock options on February 10, 2025, with an exercise price of $1.81.
• These options vest over a 4-year period, with 25% vesting on the first anniversary and the remaining options vesting monthly over the subsequent 36 months.
• The options expire on February 10, 2035.
• Following the transaction, Himmelreich directly owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing key personnel.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules, such as the 4-year schedule described, are typical in such grants.
• The specific terms of the grant (number of options, exercise price, vesting schedule) would need to be compared to those of peer companies to assess its competitiveness.

Stakeholder Impact

• The stock option grant could potentially incentivize the Head of Finance to improve company performance, benefiting shareholders.

Key Dates